Go to Top

Bibliografía

Nuestros productos están basados en los siguientes estudios:

  1. Primer ensayo clínico utilizando iVYLISA GIP-Stool: Comino I., Real A., Vivas S., Síglez M.A., Caminero A., Nistal E., Casqueiro J., Rodríguez Herrera A., Cebolla A. and Sousa C. Fecal gluten peptides reveal limitations of serological test and food questionnaires for monitoring gluten-free diet in celiac disease patients. American Journal of Gastroenterology. 2016; 10.1038/agj.2016.439.
  2. Primer estudio empleando nuestra tecnología para la detección de GIP en las muestras de orina: Moreno, ML., Cebolla, A Muñoz-Suano A, Carrillo-Carrion C, Sousa C. Detection of gluten inmunogenic peptides in the urine of patients with coeliac disease reveals trangressions in the gluten-free diet and incomplete mucosal healing. Gut, (2015) gutjnl-2015-310148.
  3. Primer estudio empleando nuestra tecnología para la detección de GIP en las muestras de heces: Comino I., Real A., Vivas S., Síglez M.A., Caminero A., Nistal E., Casqueiro J., Rodríguez Herrera A., Cebolla A. and Sousa C. Monitoring of gluten-free diet compliance in celiac patients by assessment of gliadin 33-mer equivalent epitopes in feces. Am. J. Clin. Nutr. 2012; 95(3): 670-677.
  4. Primera publicación en la que se utilizan anticuerpos especialmente diseñados para la detección de la fracción más tóxica del gluten: Morón B., Cebolla A., Manyani H., Álvarez-Maqueda M., Megías M., Thomas M.C., López M.C. and Sousa C. Sensitive detection of cereal fractions that are toxic to celiac disease patients by using monoclonal antibodies to a main immunogenic wheat peptide. Am. J. Clin. Nutr. 2008; 87:405-414.

Otros estudios:

  1. Sapone A., Bai J., Ciacci C., Dolinsek J., Green P., Hadjivassiliou M., Kaukinen K., Sanders D., Schumann M., Ullrich R., Villalta D., Volta C. and Fassano A. Spectrum of gluten-related disorders: consensus on new nomenclature and classification. BMC Med. 2012; 10: 1-13.
  2. Mariné M., Farre C., Alsina M., Vilar P., Cortijo M., Salas A., Fernández-Bañares F., Rosinach M., Santaolalla R., Loras C., Marquès T., Cusì V., Hernández M.I., Carrasco A., Ribes J., Viver J.M. and Esteve M. The prevalence of coeliac disease is significantly higher in children compared with adults. Aliment. Pharmacol. Ther. 2011; 33: 477-486.
  3. Pham-Short A., Donaghue K.C., Ambler G., Chan A.K. and Craig M.E. Short report: Epidemiology. Coeliac disease in Type 1 diabetes from 1990 to 2009: higher incidence in young children after longer diabetes duration. Diabetic Med. 2012; 29: e286-289.
  4. Murray J., McLachlan S., Adams P., Eckfeldt J., Garner C., Vulpe C., Gordeuk V., Brantner T., Leiendecker-Foster C., Killeen A., Acton R., Barcellos L., Nickerson D., Beckman K., McLaren G. and McLaren C. Association Between Celiac Disease and Iron Deficiency in Caucasians, but Not Non-Caucasians. Clin. Gastroenterol. H. 2013; 11: 808-814.
  5. Gottlieb K., Dawson J., Hussain F. and Murray J. Development of drugs for celiac disease: review of endpoints for Phase 2 and 3 trials. Gastroenterology Report. 2015; 26:1-12.
  6. Hall N., Rubin G. and Charnock A. Intentional and inadvertent non-adherence in adult coeliac disease. Appetite. 2013; 68: 56-62.
  7. Nachman F., Planzer del Campo M., González A., Corzo L., Vázquez H., Sfoggia C., Smecuol E., Pinto Sánchez M., Niveloni S., Sugai E., Mauriño E. and Bai J. Long-term deterioration of quality of life in adult patients with celiac disease is associated with treatment noncompliance. Digest. Liver Dis. 2010; 42: 685-691.
  8. Dessi M., Noce A., Vergovich S., Noce G. and Daniele N. Safety Food in Celiac Disease Patients: A systematic Review. Food Nutr. Sci. 2013; 4:55-74.
  9. Lanzini A., Lanzarotto F., Villanacci V., Mora A., Bertolazzi S., Turini D., Carella G., Malagoli A., Ferrantes G., Cesana M. and Ricci C. Complete recovery of intestinal mucosa occurs very rarely in adult coeliac patients despite adherence to gluten-free diet. Aliment. Pharmacol. Ther. 2009; 29: 1299-1308.
  10. Sharkey L.M., Corbett G., Currie E., Lee J., Sweeney N. and Woodward J.M. Optimising delivery of care in celiac disease – comparison of the benefits of repeat biopsy and serological follow-up. Aliment. Pharm. and Ther. 2013; 38: 1278-1291.
  11. Lebwohl B., Granath F., Ekbom A., Smedby K., Murray J., Neugut A., Green P. and Ludvigsson F. Mucosal healing and risk for lymphoproliferative malignancy in celiac disease. Ann Intern. Med. 2013; 159: 169-175.
  12. Hollon J., Cureton P., Martín M., Puppa L. and Fasano A. Trace gluten contamination may play a role in mucosal and clinical recovery in a subgroup of diet-adherent non-responsive celiac disease patients. BMC Gastroenterol. 2013; 13:40.
  13. Malamut G. and Cellier C. Refractory celiac disease. Expert Rev. Gastroenterol. Hepatol. 2014; 8(3): 323-328.
  14. Rodrigo L. and Peña S. Celiac Disease and Non-Celiac Gluten Sensitivity. 2014. 1st edition. OmniaScience. htp://dx.doi.org/10.3926/oms.223.
  15. Comino I., Real A., Lorenzo L., Cornell H., López-Casado M.A., Barro F., Lorite P., Torres I., Cebolla A. and Sousa C. Diversity in oat potential immunogenicity: basis for the selection of oat varieties with no toxicity in coeliac disease. Gut. 2011; 60:915-922.
  16. Green P., Lebwohl B. and Greywoode R. Celiac Disease. Clin. Rev. Allerg. Immu. 2015; 135: 1099-106.
  17. Kerkar N., Hadzic N., Davies ET., Portmann B., Donaldson PT., Rela M., Heaton ND., Vergani D. and Mieli-Vergani G. De-novo autoimmune hepatitis after liver transplantation. Lancet. 1998; 351: 409-413.
  18. Jones DE., James OF., Portmann B., Burt AD., Williams R. and Hudson M. Development of autoimmune hepatitis following liver transplantation for primary biliary cirrhosis. Hepatology. 1999; 30:53-47.
  19. Aguilera I., Wichmann I., Sousa JM., Bernardos A., Franco E., García Lozano JR. and Nuñez-Roldán A. Antibodies against glutathione S-transferase T1 (GSTT1) in patients with de novo immune hepatitis following liver transplantation. Clin. Exp. Immunol. 2001; 126:535-539.
  20. Aguilera I., Sousa JM., Gavilan F., Bernardos A., Wichmann I. and Nuñez-Roldan A. Glutathione S-transferase T1 mismatch constitutes a risk factor for de novo immune hepatitis after liver transplantation. Liver Traspl. 2004; 10: 1166-1172.
  21. Rodríguez-Mahou M., Salcedo M., Fernández-Cruz E., Tiscar JL., Banares R., Clemente G., Vicario JL., Alvarez E. and Rodríguez-Sainz C. Antibodies against glutathione S-transferase T1 (GSTT1) in patients with GSTT1 null genotype as prognostics marker: long-term follow-up after liver transplantation. Transplantation. 2007; 83: 1126-1129.